HSP90 inhibition depletes DNA repair proteins to sensitize acute myelogenous leukemia to nucleoside analog chemotherapeutics

Leuk Lymphoma. 2019 Sep;60(9):2308-2311. doi: 10.1080/10428194.2019.1571197. Epub 2019 Feb 18.

Affiliations

¹ Division of Hematology, Department of Internal Medicine, The Ohio State University , Columbus , OH , USA.
² Division of Neuro-oncology, Department of Neurosurgery, The Ohio State University , Columbus , OH , USA.
³ Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center , Houston , TX , USA.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / pharmacology*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Arabinonucleosides / pharmacology*
Arabinonucleosides / therapeutic use
Benzamides / pharmacology*
Benzamides / therapeutic use
Cell Line, Tumor
Cytosine / analogs & derivatives*
Cytosine / pharmacology
Cytosine / therapeutic use
DNA Breaks, Double-Stranded / drug effects
DNA Repair / drug effects
Drug Resistance, Neoplasm / drug effects*
Drug Resistance, Neoplasm / genetics
HSP90 Heat-Shock Proteins / antagonists & inhibitors*
HSP90 Heat-Shock Proteins / metabolism
Humans
Isoindoles / pharmacology*
Isoindoles / therapeutic use
Leukemia, Myeloid, Acute / drug therapy*
Leukemia, Myeloid, Acute / genetics
Leukemia, Myeloid, Acute / pathology

Substances

Arabinonucleosides
Benzamides
HSP90 Heat-Shock Proteins
Isoindoles
Cytosine
(2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone
sapacitabine

Grants and funding